Cardiovascular-Kidney-Metabolic syndrome, CKM for short, is a clinical framework the American Heart Association formally defined in 2023 that is now getting a new wave of attention after research published in Nature Reviews Nephrology this spring found that most adults already meet the criteria for at least an early stage of it.
The Independent's coverage this week is bringing it to a new audience. Here is what it actually is.
The core insight behind CKM is that heart disease, chronic kidney disease, obesity and metabolic conditions like diabetes are not separate problems that happen to show up in the same person. They feed each other.
Kidney dysfunction worsens cardiovascular risk. Metabolic dysfunction accelerates kidney damage. Obesity drives all of it.
Damage in any one system cascades into the others in a loop that is much harder to stop once it starts than if you had caught it at the beginning.
The AHA staged the syndrome from 0 to 4. Stage 0 is healthy. Stage 1 is excess or dysfunctional body fat.
Stage 2 is metabolic risk factors, high blood sugar, high blood pressure, high cholesterol, or early kidney disease. Stage 3 is subclinical cardiovascular disease alongside those factors.
Stage 4 is established heart or kidney failure. Research based on national health data finds approximately 90 percent of US adults are at Stage 1 or higher.
Roughly one in three has three or more CKM risk factors simultaneously.
The reason it matters to name it is the treatment. Managing heart disease, kidney disease and diabetes as separate conditions, in separate specialist appointments, with separate medications that sometimes conflict, is significantly less effective than managing the whole interconnected system together.
That is what CKM is asking doctors to do differently.